ArticleFrontiers in immunology2025
NMB promotes the progression of colorectal cancer by regulating the NF-κB/P65 signaling pathway.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Hsa-miR-1276 in peripheral blood mononuclear cells as a potential biomarker for rheumatoid arthritis.Clinical and experimental medicine · 2026Article
- Integrative single-cell and genomic analysis reveals NMB as a driver of metastatic adaptation in esophageal squamous cell carcinoma via metabolic rewiring and immune evasion.Frontiers in cell and developmental biology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Colorectal carcinoma (CRC) ranks as the fourth most prevalent malignancy globally. Neuromedin B (NMB) and its corresponding receptor have been implicated in the pathogenesis of multiple neoplastic conditions. Nevertheless, the specific involvement of NMB in CRC progression remains poorly characterized. Methods: To investigate the differential expression of NMB, data were extracted from the TCGA and GEO databases, supplemented by tissue microarrays derived from clinical specimens. Prognostic significance was assessed through Kaplan-Meier survival analysis, ROC curve evaluation, Cox proportional hazards regression, clinical correlation studies, and nomogram construction. Experimental validation of NMB expression in CRC was performed using qRT-PCR, western blotting, immunohistochemistry, and ELISA techniques. Functional characterization of NMB's tumor-regulatory capacity was conducted through colony formation assays, MTT proliferation tests, wound healing experiments, and transwell migration/invasion assays. Mechanistic insights were obtained by identifying upstream regulatory proteins via co-immunoprecipitation and exploring potential signaling pathways through gene set enrichment analysis (GSEA) combined with western blot validation. Results: Analysis of clinical data revealed that NMB exhibits markedly elevated expression levels in CRC tissues, with higher expression correlating significantly with poor prognosis. Receiver operating characteristic curve analysis validated NMB's utility as a reliable prognostic biomarker for survival outcomes. Importantly, multivariate Cox regression analysis demonstrated NMB's independent prognostic value in CRC patients. Conclusion: NMB exhibits significant overexpression in colorectal cancer, demonstrating promising potential as a dual-functional biomarker for both diagnostic identification and prognostic evaluation in CRC cases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.